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The rationale for antiangiogenic therapy
in cancer is multifaceted. Growing tumors
produce angiogenic factors to recruit host
vasculature or circulating vascular prog-
enitor cells to provide the substrate for
the synthesis of new blood vessels.
These angiogenic vessels provide a con-
duit for blood flow to deliver nutrients and
oxygen to meet the metabolic demands
of the growing neoplasm. In turn, as the
tumor enlarges, necrotic and hypoxic
zones in tumors are created due to the
immature nature of tumor vasculature. In
certain regions of tumors, blood vessels
contain the proper repertoire of endothe-
lial-lined, pericyte-enwrapped vessels
that may provide nutritive blood flow,
while in other areas, the vessels are high-
ly permeable, ectatic, and lack stabilizing
pericytes.These immature vessels do not
provide nutritive flow and create a hypox-
ic environment with high intratumoral
hydrostatic pressures, thus reducing the
sensitivity of tumor cells to radiotherapy
as well as impeding the delivery of
chemotherapeutic drugs (Jain, 2003).
Clearly, antiangiogenic agents reduce
the vascular density of tumors and
ultimately tumor burden (Kerbel and
Folkman, 2002). There are data suggest-
ing that antiangiogeneic agents may fur-
ther increase hypoxia in the remaining
tumor cells by choking off the blood sup-
ply to tumors, thus perpetuating the cycle
of hypoxia, tumor growth, and continued
angiogenesis. In murine models of solid
and metastatic tumors, antiangiogenic
agents greatly eliminate tumor blood ves-
sels and tumor burden. However, in
human cancers, antiangiogenic agents
need to be combined with other therapies
to show a significant clinical outcome.
There are many potential reasons for the
lack of a robust effect of monotherapy,
including dosing regimens of the antian-
giogenic drugs, but to date, combination
therapy is the standard of care. Analysis
of how antiangiogenic agents reduce ves-
sel density shows that these drugs reduce
vascular permeability, destroy “less
mature” vessels, and increase the recruit-
ment of pericytes to stabilize other ves-
sels in tumors. This apparent stabilization
has been termed the normalization win-
dow, defined as a period of time where
tumor blood flow and oxygenation tran-
siently increases, thus providing an
opportunity to better deliver chemothera-
peutic agents and radiation therapy (Jain,
2001). After continued treatment beyond
the normalization window, pericyte-
replete vessels are also destroyed. The
molecular basis for normalization is not
known, but the paper by Winkler et al.
(2004) in this issue of Cancer Cell sheds
insights into the mechanisms of pericyte
recruitment after inhibition of angiogene-
sis with an antibody that blocks VEGF
receptor 2, DC101.
In order to gain insights into the
kinetics of the normalization window, the
authors compared the doubling time of
U87 glioma tumors implanted into a cra-
nial window model in mice. Mice received
either ionizing radiation or treatment with
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Antiangiogenic therapy: Creating a unique “window”of opportunity
Antiangiogenic therapy for solid tumors clearly destroys tumor vasculature and reduces tumor growth. As an unexpected
bonus, drugs that neutralize VEGF signaling generate a “normalization window” for tumor vasculature.This occurs via the
recruitment of pericytes to the tumor vasculature, an effect associated with the transient stabilization of vessels and
improved oxygen delivery to hypoxic zones. The normalization process is mediated by angiopoietin-1 and matrix metallo-
proteinases and creates a window of opportunity for improved sensitivity to ionizing radiation and the delivery of
chemotherapeutic drugs.
Figure 1. Schematic diagram depicting the
mechanism of vascular normalization by
DC101
Untreated tumor vasculature is characterized
by dilated and tortuous vessels, thickened
basement membrane (BM), and little peri-
cyte coverage. DC101 treatment rapidly
elicits an early phase of vascular normaliza-
tion (marked by the box) in which there is an
increase in pericyte recruitment mediated by
the Ang-1, since a Tie-2 blocking Ab (α-Tie 2),
a peptide antagonist for Tie 2 or siRNA treat-
ment against Ang-1, effectively reduces the
pericyte coverage. There is a concomitant
decrease in blood vessel diameter with no
change in vessel density, a decrease in BM
thickness, and decrease in tumor hypoxia.
The changes in BM thickness are due to
increases in collagenase activity, as MMP
inhibitor can block this response. The
changes mediated by DC101 in tumor extra-
cellular matrix and vasculature open a win-
dow in which tumor oxygenation increases
temporarily, thus allowing for effective cyto-
toxic killing of tumor cells by ionizing radia-
tion. During the later phase of DC101
treatment, there is a relapse of tumor hypoxia
and gradual loss of pericyte coverage as
blood vessel density continues to drop.
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DC101 or combinations of the two.
Remarkably, the authors show a syner-
gistic effect of combination therapy in
delaying tumor doubling time by more
than 21 days only in a restricted window
of treatment time, namely radiation ther-
apy given on days 4–6 after the start of
DC101 treatment. Upon closer examina-
tion, there was a marked decrease in
tumor hypoxia during DC101 treatment
beginning on day 2 and lasting through
day 5. The ability of DC101 to increase
tumor oxygenation (i.e., decrease the
hypoxic tumor fraction) supports the idea
that anti-VEGF therapy redistributes
blood flow to hypoxic zones, thereby pro-
viding oxygen for radiation-induced DNA
damage and cell death (Figure 1).
To further probe the potential mech-
anisms to explain how VEGFR2 block-
ade reduces tumor hypoxia, the authors
show that DC101 mediates its effect by
increasing pericyte recruitment to tumor
blood vessels, thereby stabilizing or
normalizing the once leaky, dilated
tumor vasculature. This normalization
process has been previously described
by a reduction in abnormal, leaky tumor
vessels (lacking stabilizing support cells
or pericytes) and an increase in the
number of anatomically patent vessels
(enveloped by pericytes). Treatment
with DC101 dramatically increases the
number of pericyte-covered vessels
detected, supporting previous studies
using either VEGFR inhibitors or neu-
tralizing antibodies (Inai et al., 2004;
Tong et al., 2004). At first glance, these
data are reminiscent of data showing
that genetic withdrawal of VEGF can
lead to preferential pruning of non-peri-
cyte-covered vessels (Abramovitch et
al., 1999; Benjamin et al., 1999). To dis-
tinguish whether the observed increas-
es in pericyte coverage are due to
vessel pruning or actual recruitment of
pericytes, this paper elegantly docu-
ments the power of serial imaging of liv-
ing blood vessels in tumors and shows
that neutralization of VEGF signaling
with DC101 increases pericyte recruit-
ment without changing overall tumor
vascular density. The increase in peri-
cyte coverage is maintained until day 5,
when vessel density significantly drops,
partly due to an increase in vascular cell
apoptosis. After continued therapy (8
days), pericyte-covered vessels decrease
in number concomitant with reductions
in vascular density, indicating that peri-
cyte-covered vessels are still subject to
regression, similarly observed during
VEGF withdrawal (Baluk et al., 2004).
A previous study by Jain’s group
showed that treatment of MCaIV tumors
with DC101 reduced angiopoietin-2
(Ang-2) expression, raising the potential
involvement of the angiopoietin family
members during normalization (Tong et
al., 2004). Interestingly, in the present
study, treatment with DC101 upregulates
the synthesis of Ang-1 during the phase
of pericyte coverage of tumor vessels.
This effect appears to be functionally rel-
evant, since treatment of the cancer cells
with an antibody that blocks the receptor
for Ang-1 and Ang-2 (Tie2) 1, a Tie-2
blocking peptide and siRNA against Ang-
1, reduces DC101-stimulated pericyte
recruitment. More impressively, DC101-
triggered decreases in the hypoxic tumor
fraction were abrogated by the Tie-2
blocking peptide. The role of Ang-1 in
promoting pericyte recruitment was ini-
tially suggested based on analysis of
mice deficient in Ang-1. However, the
mechanism of how Ang-1 performs the
task of pericyte recruitment, as well as
how neutralization of VEGF could lead to
Ang-1 gene expression, is not known.
Presumably, tumor-derived Ang-1 acts
on endothelial cell Tie 2 to generate an
additional signal or signals to recruit
pericytes; however, the nature of signal
leading to pericyte recruitment is
unknown. Current dogma supports the
idea that Ang-1 generally promotes ves-
sel maturation, whereas Ang-2 may
serve to antagonize the action of Ang-1
in the absence of VEGF. However, the
waters are a bit murky, since the role of
Ang-1 in tumor angiogenesis is still
under debate. Although many tumors
overexpress Ang-1, the regulation of
Ang-1 expression by hypoxia, cytokines,
and other growth factors has yielded
equivocal results (Metheny-Barlow and
Li, 2003).
In addition to Ang-1 being an endothe-
lial cell survival factor (Papapetropoulos et
al., 1999), it also reduces vascular leak-
age (Thurston et al., 1999). However, the
decrease in vascular permeability during
the entire course of DC101 treatment did
not quite mirror the pericyte coverage
kinetics.The ability of Ang-1 to inhibit per-
meability was thought to be due to
enhancement of cell-to-cell junctions as
well as stabilization of blood vessels by
promoting mural cell recruitment, yet
DC101 blockade in permeability is con-
tinually observed even on day 8, when
Ang-1 and pericyte coverage are
decreased to control levels. This raises
interesting questions as to whether other
mediators, such as PDGF or the loss of
nitric oxide, can affect permeability and
promote normalization. Clearly, the
mechanisms and mediators of pericyte
recruitment in regulating tumor vascular
permeability need to be further
delineated.
In addition to the changes in peri-
cyte recruitment during DC101 treat-
ment, the authors show a dramatic
change in basement membrane (BM)
architecture. DC101 reduces BM thick-
ness and increases type IV collagenase
activity surrounding the blood vessels.
Administration of the Tie2 blocking anti-
body did not reduce the thinning of BM
mediated by DC101, implying that other
regulatory mechanisms are likely
responsible for the altered extracellular
matrix. The data showing a thinning of
the BM is in contrast to other studies
using VEGFR inhibitors such as
AG013736, VEGF-Trap, or VEGF with-
drawal. These modalities led to eventual
regression of the tumor vasculature
(Baluk et al., 2004; Inai et al., 2004)
despite the persistent presence of BM,
even after complete disappearance of
CD31-positive blood vessels. These BM
ghosts were suggested to serve as
scaffolds for potential revascularization,
thus presenting it as another attractive
therapeutic target. In addition, Jain’s
group previously reported BM thicken-
ing after DC101 treatment in another
tumor model (Tong et al., 2004). The
confounding data on VEGFR blockade
and BM modification illustrate that dis-
rupting VEGF-VEGF receptor signaling
can dynamically alter the BM structure,
influencing tumor vasculature and
growth.
Regardless of the precise molecular
mechanisms of how anti-VEGF therapy
synergizes with radiation to reduce
tumor size, the paper by Winkler et al.
importantly documents the potential
mechanisms that govern the generation
of a normalization window and provides
a rational basis for the combination ther-
apy of antiangiogenic drugs with radia-
tion and perhaps other forms of
chemotherapy. Clearly, this work will
increase excitement in defining the
mechanisms of the normalization win-
dow in humans and in harnessing oppor-
tunities to improve the sensitivity of
tumors to radio- and chemotherapy.
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Human cancer stem cells, identified in
acute myelogenous leukemia (Bonnet and
Dick, 1997), myeloid blast crisis of chronic
myelogenous leukemia (Jamieson et al,
2004), breast cancer (Al-Hajj et al., 2003),
and brain tumors (Singh et al., 2003),
share functional properties with normal
stem cells, such as high proliferative
potential, some differentiation capacity,
and the ability to be serially transplanted
(reviewed in Passegué et al., 2003).
Signaling pathways involved in the regula-
tion of normal stem cell self-renewal are
frequently mutated or epigenetically acti-
vated in cancer, indicating that self-renew-
al, i.e. a cell division that produces
progeny identical to the parental cell, is a
vital property of cancer stem cells
(reviewed in Reya et al., 2001). Targeted
disruption of cancer stem cell self-renewal
would represent a novel therapeutic strat-
egy that could significantly reduce the
capacity of a tumor to propagate itself, and
could be employed in the eradication of a
broad spectrum of cancers, including
leukemias.
Chronic myelogenous leukemia
(CML) and most types of acute myeloge-
nous leukemia (AML) are induced by
leukemia-associated fusion proteins that
generally function as aberrantly activat-
ed signaling mechanisms or positive or
negative transcriptional regulators, and
directly interfere with the hematopoietic
differentiation program. While their
mechanism of action is relatively well
understood, little is known about their
developmental requirement for transfor-
mation and the role of self-renewal in this
process. In this issue of Cancer Cell,
Huntly et al. (2004) have studied in the
mouse the target cell requirement of two
human leukemia-associated fusion pro-
teins, MOZ-TIF2 and BCR-ABL. MOZ-
TIF2, an AML-associated fusion gene
resulting from the inv (8)(p11q13)-
induced juxtaposition of the MOZ chro-
matin remodeling gene and the TIF2
nuclear receptor transcriptional coactiva-
tor, is thought to modulate the transcrip-
tional activity of target genes through
aberrant histone acetylation. In contrast,
BCR-ABL, the hallmark of CML, gives
rise to a constitutively active protein tyro-
sine kinase, which endows primitive
stem and progenitor cells with a prolifer-
ative and survival advantage (reviewed
in Daley, 2004). Using retroviral gene
transfer combined with in vitro serial
replating assays and leukemic transplan-
tation into lethally irradiated recipient
mice, they compared the capacity of
MOZ-TIF2 and BCR-ABL to enhance the
self-renewal potential of normal murine
bone marrow mononuclear cells, highly
purified hematopoietic stem cells (HSC),
and more committed progenitors includ-
ing common myeloid progenitors (CMP)
and granulocyte-monocyte progenitors
(GMP). They also included critical con-
trols, such as MOZ-TIF2 point mutants
that lacked transforming activity, to
exclude a contribution by retroviral inser-
tional mutagenesis to the observed
leukemogenic effects. The results pre-
sented in this paper demonstrate that
MOZ-TIF2, but not BCR-ABL, endows
myeloid progenitors with self-renewal
Chronic versus acute myelogenous leukemia: A question of 
self-renewal
Leukemia stem cells are defined as transformed hematopoietic stem cells or committed progenitor cells that have ampli-
fied or acquired the stem cell capacity for self-renewal, albeit in a poorly regulated fashion. In this issue of Cancer Cell,
Huntly and colleagues report a striking difference in the ability of two leukemia-associated fusion proteins, MOZ-TIF2 and
BCR-ABL, to transform myeloid progenitor populations. This rigorous study supports the idea of a hierarchy among
leukemia-associated protooncogenes for their ability to endow committed myeloid progenitors with the self-renewal
capacity driving leukemic stem cell propagation, and sheds new light on the pathogenesis of chronic and acute myeloge-
nous leukemias.
